|Videos|June 7, 2023
Educating Patients and Caregivers on Infection Risks of Anti-BCMA Bispecific Antibodies in MM Treatment
The panel discusses how to educate patients and caregivers on infections risks when receiving an anti-BCMA bispecific antibody.
Advertisement
Episodes in this series
Advertisement
Related to this article
The FDA’s decision on iberdomide is a “landmark approval” for those with multiple myeloma, according to Surbhi Sidana, MD.
Full results from the phase 3 CERVINO trial assessing etentamig in relapsed/refractory multiple myeloma will be shared at the 23rd IMS Annual Meeting.
Advertisement
Advertisement
Trending on CancerNetwork
1
IASO208 Receives FDA IND Clearance for Relapsed/Refractory B-Cell Lymphoma
2
WCLC 2026: How Will The Small Cell Lung Cancer Paradigm Change?
3
Novel Macrocyclic EGFR TKI Shows Responses in EGFR C797S–Positive NSCLC
4
Secondary T-Cell Malignancies: Identifying and Counseling After CAR T-Cell Therapy
5